Keith Katkin
CIK 1314596 · PEO;CEO/Urovant Sciences, Inc. · last filed 2026-05-04
Keith Katkin is a PEO;CEO/Urovant Sciences, Inc. who has filed 89 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for EBS, was dated May 4, 2026. Across all open-market trades the lifetime net is −$11.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.38M
7
89
-$11.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EBS | Director | 111,775 | $7.31 | $817.1K | -$177.6K | 6 | 2026-05-04 |
| SNDX | Director | 124,000 | $19.63 | $2.43M | -$786.1K | 15 | 2026-02-06 |
| ELDN | Director | 8,575 | $3.40 | $29.2K | $0 | 5 | 2026-01-16 |
| RIGL | Director | 2,500 | $38.50 | $96.2K | $0 | 7 | 2021-05-21 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 4 | 2020-09-15 |
| Urovant Sciences Ltd. (UROV) Delisted | PEO;CEO/Urovant Sciences, Inc. | 274,892 | $16.24 | $4.46M | -$1.53M | 7 | 2020-02-21 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | President and CEO | 914,249 | — | — | -$9.20M | 42 | 2014-12-18 |
Recent Filings
89 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-04 | EBS | Mixed | +9,863 | -$128.2K | EDGAR |
| 2026-04-30 | EBS | Notice (144) | −15,481 | -$128.1K | EDGAR |
| 2026-02-06 | SNDX | Grant (A) | +24,000 | $0 | EDGAR |
| 2026-01-16 | ELDN | Exer (M) | +8,575 | $0 | EDGAR |
| 2025-05-28 | EBS | Sell (S) | −7,844 | -$49.4K | EDGAR |
| 2025-05-23 | EBS | Notice (144) | −7,844 | -$49.4K | EDGAR |
| 2025-05-19 | SNDX | Buy (P) | +10,000 | $91.1K | EDGAR |
| 2025-05-02 | EBS | Grant (A) | +34,403 | $0 | EDGAR |
| 2025-02-07 | SNDX | Grant (A) | +25,000 | $0 | EDGAR |
| 2025-01-13 | ELDN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.